mynth
03/2017

UNITHER acquired by ARDIAN

FRANCE Life Sciences / Pharma & Biotech / CDMO EV 500M - 1.5b EUR

Context

Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.

UNITHER, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Global leader in sterile unit-dose manufacturing using Blow-Fill-Seal (BFS) technology. The group provides contract development and manufacturing services for pharmaceutical companies, specializing in ophthalmology, respiratory diseases, and saline solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2016
2015

Other operations with UNITHER

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
DateAcquirerTargetCountrySector
10/2022IK PARTNERSUNITHERFRANCECDMO

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of UNITHER by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: ardian